Nicolas Pécuchet

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

<i>TP53, STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

Jérôme Biton, Audrey Mansuet‐Lupo, Nicolas Pécuchet et al. · Clinical Cancer Research · 2018 · 361 citations

Life Sciences, Immunology, Oncology +17

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort

Julien Mazières, Gérard Zalcman, Lucio Crinò et al. · Journal of Clinical Oncology · 2015 · 350 citations · Full text

Medicine, Oncology, Pharmacology +14

Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker

Daniel Pietrasz, Nicolas Pécuchet, Fanny Garlan et al. · Clinical Cancer Research · 2016 · 267 citations · Full text

Medicine, Molecular Medicine, Oncology +17